Cargando…

Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma

Background: Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy, lacking a unified staging system and treatment. Management at a single center was retrospectively evaluated to inform future treatment options and prognostic factors. Methods: Clinical data of 64 consecutive ENB patients, includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Qian, Tian, Yifu, He, Yihong, Xie, Qiongxuan, Ou, Ludi, Wang, Min, Chen, Wen, Wei, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969639/
https://www.ncbi.nlm.nih.gov/pubmed/33747939
http://dx.doi.org/10.3389/fonc.2021.624960
_version_ 1783666266945355776
author Zeng, Qian
Tian, Yifu
He, Yihong
Xie, Qiongxuan
Ou, Ludi
Wang, Min
Chen, Wen
Wei, Rui
author_facet Zeng, Qian
Tian, Yifu
He, Yihong
Xie, Qiongxuan
Ou, Ludi
Wang, Min
Chen, Wen
Wei, Rui
author_sort Zeng, Qian
collection PubMed
description Background: Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy, lacking a unified staging system and treatment. Management at a single center was retrospectively evaluated to inform future treatment options and prognostic factors. Methods: Clinical data of 64 consecutive ENB patients, including prognostic factors and treatment methods, were reviewed retrospectively. Data were collected to calculate overall survival (OS) and progression free survival (PFS). Results: The majority of tumors 84.4% were within Kadish C stage, 79.7% were within T3 or T4, and 64.0% were within Hyams grade III or IV. A total of 50 (78.1%) patients received surgery and combined radiotherapy with or without chemotherapy, 10 (15.6%) received surgery with or without chemotherapy alone, and 4 (6.3%) received radiotherapy with or without chemotherapy alone. The majority of patients (79.7%) underwent endoscopic resection (endoscopic and endoscopically assisted). Surgery combined with radiotherapy with or without chemotherapy resulted in significantly better OS (84.4 vs. 50.6%, 84.4 vs. 37.5%) compared to surgery alone and radiotherapy alone (P = 0.0064). Endoscopic surgery group (endoscopic and endoscopically assisted) resulted in significantly better 5-year PFS (61.7 vs. 22.2%) compared to the open surgery group (P < 0.001). Although endoscopic surgery group was not a statistically significant predictor of 5-year OS (P = 0.54), the 5-year OS was 79.3% for the endoscopic surgery group and 76.2% for the open surgery group. A Cox regression analysis identified intracranial extension and surgery combined with radiotherapy as independent factors affecting 5-year OS while cervical lymph node metastasis and Hyams grade IV as independent factors affecting 5-year PFS. Conclusion: Our findings suggest that surgery combined with radiotherapy is the best treatment approach for ENB. For advanced tumors, endoscopic surgery is an effective treatment, and its survival rate is equal to or better than open surgery.
format Online
Article
Text
id pubmed-7969639
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79696392021-03-19 Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma Zeng, Qian Tian, Yifu He, Yihong Xie, Qiongxuan Ou, Ludi Wang, Min Chen, Wen Wei, Rui Front Oncol Oncology Background: Esthesioneuroblastoma (ENB) is a rare sinonasal malignancy, lacking a unified staging system and treatment. Management at a single center was retrospectively evaluated to inform future treatment options and prognostic factors. Methods: Clinical data of 64 consecutive ENB patients, including prognostic factors and treatment methods, were reviewed retrospectively. Data were collected to calculate overall survival (OS) and progression free survival (PFS). Results: The majority of tumors 84.4% were within Kadish C stage, 79.7% were within T3 or T4, and 64.0% were within Hyams grade III or IV. A total of 50 (78.1%) patients received surgery and combined radiotherapy with or without chemotherapy, 10 (15.6%) received surgery with or without chemotherapy alone, and 4 (6.3%) received radiotherapy with or without chemotherapy alone. The majority of patients (79.7%) underwent endoscopic resection (endoscopic and endoscopically assisted). Surgery combined with radiotherapy with or without chemotherapy resulted in significantly better OS (84.4 vs. 50.6%, 84.4 vs. 37.5%) compared to surgery alone and radiotherapy alone (P = 0.0064). Endoscopic surgery group (endoscopic and endoscopically assisted) resulted in significantly better 5-year PFS (61.7 vs. 22.2%) compared to the open surgery group (P < 0.001). Although endoscopic surgery group was not a statistically significant predictor of 5-year OS (P = 0.54), the 5-year OS was 79.3% for the endoscopic surgery group and 76.2% for the open surgery group. A Cox regression analysis identified intracranial extension and surgery combined with radiotherapy as independent factors affecting 5-year OS while cervical lymph node metastasis and Hyams grade IV as independent factors affecting 5-year PFS. Conclusion: Our findings suggest that surgery combined with radiotherapy is the best treatment approach for ENB. For advanced tumors, endoscopic surgery is an effective treatment, and its survival rate is equal to or better than open surgery. Frontiers Media S.A. 2021-03-04 /pmc/articles/PMC7969639/ /pubmed/33747939 http://dx.doi.org/10.3389/fonc.2021.624960 Text en Copyright © 2021 Zeng, Tian, He, Xie, Ou, Wang, Chen and Wei. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zeng, Qian
Tian, Yifu
He, Yihong
Xie, Qiongxuan
Ou, Ludi
Wang, Min
Chen, Wen
Wei, Rui
Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma
title Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma
title_full Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma
title_fullStr Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma
title_full_unstemmed Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma
title_short Long-Term Survival Outcomes and Treatment Experience of 64 Patients With Esthesioneuroblastoma
title_sort long-term survival outcomes and treatment experience of 64 patients with esthesioneuroblastoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969639/
https://www.ncbi.nlm.nih.gov/pubmed/33747939
http://dx.doi.org/10.3389/fonc.2021.624960
work_keys_str_mv AT zengqian longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma
AT tianyifu longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma
AT heyihong longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma
AT xieqiongxuan longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma
AT ouludi longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma
AT wangmin longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma
AT chenwen longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma
AT weirui longtermsurvivaloutcomesandtreatmentexperienceof64patientswithesthesioneuroblastoma